Gold Investment Management Ltd. Acquires 7,526 Shares of Pfizer Inc. (NYSE:PFE)

Gold Investment Management Ltd. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 16.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,596 shares of the biopharmaceutical company’s stock after buying an additional 7,526 shares during the quarter. Gold Investment Management Ltd.’s holdings in Pfizer were worth $1,487,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in PFE. Harbour Investments Inc. boosted its position in shares of Pfizer by 6.1% during the third quarter. Harbour Investments Inc. now owns 61,216 shares of the biopharmaceutical company’s stock valued at $2,031,000 after buying an additional 3,507 shares during the period. Financial Gravity Asset Management Inc. boosted its holdings in Pfizer by 812.2% in the third quarter. Financial Gravity Asset Management Inc. now owns 4,570 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 4,069 shares during the last quarter. OLD National Bancorp IN boosted its holdings in Pfizer by 26.2% in the third quarter. OLD National Bancorp IN now owns 200,937 shares of the biopharmaceutical company’s stock valued at $6,665,000 after purchasing an additional 41,679 shares during the last quarter. Tompkins Financial Corp raised its position in shares of Pfizer by 4.2% in the third quarter. Tompkins Financial Corp now owns 39,236 shares of the biopharmaceutical company’s stock worth $1,301,000 after acquiring an additional 1,594 shares during the period. Finally, Brown Shipley& Co Ltd raised its position in shares of Pfizer by 3.6% in the third quarter. Brown Shipley& Co Ltd now owns 21,200 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 746 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.63 during trading hours on Wednesday, hitting $28.35. 26,990,295 shares of the company’s stock traded hands, compared to its average volume of 40,022,254. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The company has a market cap of $160.65 billion, a price-to-earnings ratio of -472.42, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company’s fifty day simple moving average is $28.21 and its two-hundred day simple moving average is $27.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the firm earned $1.23 earnings per share. The firm’s revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 5.93%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $35.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.